ADVA sync solution enables major Chilean telco to roll out 5G-ready network
28.10.2019 15:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its Oscilloquartz synchronization technology is enabling one of Chile’s largest communication service providers (CSPs) to roll out LTE Advanced (LTE-A) connectivity across the country and prepare for 5G. The OSA 5430 Series and OSA 5410 Series of PTP grandmaster clocks and GNSS receivers deliver stringent phase synchronization in the core and in the access network, enabling the company to address rapidly rising customer demand for premium services such as high-definition video streaming. The deployment strengthens ADVA’s position in the market with its timing technology now synchronizing more of Chile’s major CSP networks than any other supplier’s solutions. The network is being installed by ADVA’s long-term partner Sistemas de Instrumentación Ltda.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191028005386/en/
The OSA 5430 Series and OSA 5410 Series are enabling one of Chile’s largest CSPs to roll out national LTE-A connectivity (Photo: Business Wire)
“Being selected to transform the sync network of another of Chile’s key CSPs highlights the unique benefits of our grandmaster clocks and GNSS receiver portfolio. With high-quality oscillators guaranteeing unbeatable holdover and the continual assurance of in-service sync with our built-in probes, our technology offers the most complete and comprehensive solution for advanced timing in telecom networks. It will generate value for years to come,” said Gil Biran, general manager, Oscilloquartz. “Our mission is to provide exceptional service to all of our customers. With our technology and ongoing support, we’re empowering another major company to reshape Chile’s telecommunication landscape, reaching more people than ever while continuing to deliver unrivalled quality of service.”
By deploying the small yet versatile OSA 5410 Series in the access networks, the CSP is providing advanced, time-sensitive mobile connectivity throughout Chile, including previously underserved regions. At once a mini-grandmaster, boundary clock, slave device and sync probe, ADVA’s multipurpose devices lead the industry in terms of adaptability and innovation. At its core, the company is utilizing the OSA 5430 Series, which offers full hardware redundancy, significantly reducing downtime. This high-capacity unit also provides unprecedented scale, supporting speeds of up to 10Gbit/s. Additionally, the OSA 5410 and 5430 both support assisted partial timing support (APTS) and feature Oscilloquartz’s best-in-class oven-controlled crystal oscillators, which offer exceptional holdover performance even in the most challenging conditions.
"We work closely with our partner ADVA to deliver world-class technology that ensures unbeatable quality and availability. Their Oscilloquartz grandmasters are the most advanced timing solutions on the market. Ideal for distributing ultra-precise, incredibly reliable phase and time-of-day information, these devices are now providing the heartbeat of another of Chile’s leading CSPs,” commented Danor Quinteros, CEO, Sistemas de Instrumentación Ltda. “One of the crucial elements of this deployment was bringing synchronization close to the end user where it’s most needed. The compact and feature-rich OSA 5410 devices in the access network and the high-capacity OSA 5430 in the core infrastructure will be key to delivering ever-faster speeds and latency-sensitive applications.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to- end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA Optical Networking company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at: www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005386/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
